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Recent reports estimate global annual perioperative morbidity and 
mortality rates to be ~3% and 0.5%, respectively.[1] One-third of 
deaths in patients undergoing non-cardiac surgery are cardiovascular 
in origin.[2] Myocardial ischaemia with subsequent injury is strongly 
associated with perioperative mortality.[3,4] A large multicentre 
international study in 2012 investigated the mortality associated with 
perioperative elevated troponin levels in >15 000 patients from North 
and South America, Australia, Europe and Asia (Vascular Events In 
Non-cardiac Surgery Patients Cohort Evaluation (VISION) study).[3] 
The 30-day mortality was found to be independently associated with 
myocardial injury after non-cardiac surgery (MINS) in a subsequent 
analysis of the data.[5] Ten percent of patients with myocardial injury 
died within 30 days of surgery.[5] Eighty-four percent of perioperative 
patients with myocardial injury were asymptomatic, resulting in 
missed diagnosis in the vast majority of patients with MINS.[5] 
Thirty-day mortality was found to be independently associated with 
an elevated cardiac biomarker, specifically cardiac troponin T (cTnT).
The VISION study utilised the previous fourth-generation cTnT 
test.[3] MINS has been defined as an isolated fourth-generation cTnT 
level of ≥30 ng/L (0.03 µg/mL) due to myocardial ischaemia, which 
predicted mortality with an odds ratio of 10.07 (95% confidence 
interval (CI) 7.84 - 12.94).[5] A substudy of the VISION investigation 
suggested that a suitable cut-off level for the more sensitive fifth-
generation cTnT (hs-cTnT) for a diagnosis of MINS is >33 ng/L.[6]
With regard to MINS, only a single vascular surgical cohort has 
been studied in South Africa (SA).[7-9] Because of differing patient 
characteristics and risk profiles, extrapolation of the incidence of MINS 
from international data to SA surgical patients may be inappropriate.
Objectives
The primary objective of this study was to determine the incidence 
of MINS after non-cardiac surgery in an elective elevated-risk 
surgical population in SA. The null hypothesis for this study 
was that the incidence of MINS would be similar in the SA 
study population to that described in peer-reviewed international 
reports. Secondary outcomes were the prevalence of risk factors 
such as patient demographics, surgical categories and comorbidities 
associated with MINS.
Methods
This was a prospective, single-centre observational study investigating 
the incidence of MINS at Groote Schuur Hospital, a tertiary referral 
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Background. Myocardial injury after non-cardiac surgery (MINS) is a newly recognised entity identified as an independent risk factor 
associated with increased 30-day all-cause mortality. MINS increases the risk of death in the perioperative period by ~10-fold. More than 
80% of patients with MINS are asymptomatic, so the majority of diagnoses are missed. Awareness of MINS is therefore important for 
perioperative physicians.
Objectives. To investigate the incidence of MINS after elective elevated-risk non-cardiac surgery at Groote Schuur Hospital, Cape Town, 
South Africa (SA).
Methods. Patients aged ≥45 years undergoing elective elevated-risk non-cardiac surgery were enrolled via convenience sampling. The new 
fifth-generation high-sensitivity cardiac troponin T blood test was used postoperatively to identify MINS. Preoperative troponin levels were 
not measured.
Results. Among 244 patients included in the study, the incidence of MINS was 4.9% (95% confidence interval (CI) 2.8 - 8.5), which was 
not significantly different from that in a major international prospective observational study (VISION) (8.0% (95% CI 7.5 - 8.4)); p=0.080.
Conclusions. Our SA cohort had a lower cardiovascular risk profile but a similar incidence of MINS to that described in international 
literature. The impact of MINS on morbidity and mortality is therefore likely to be proportionally higher in SA than in published 
international studies. The limited sample size and lower event rate weaken our conclusions. Larger studies are required to establish patient 
and surgical risk factors for MINS, allowing for revision of cardiovascular risk prediction models in SA.
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centre in Cape Town, SA. Patients aged ≥45 years presenting for 
elective elevated-risk non-cardiac surgery were eligible. Elevated-
risk surgery was defined as all surgery with a predicted risk of major 
adverse cardiac events of >1%. [10] This included all intra-abdominal, 
non-cardiac thoracic, joint replacement, major orthopaedic and 
vascular surgery. Patients were selected by means of convenience 
sampling from November 2014 to February 2016, and only these 
patients were included in the study.
Enrolled patients were investigated for MINS, defined as an 
elevated postoperative hs-cTnT level suspected to be due to 
myocardial ischaemia, with no other known non-ischaemic causes of 
troponin elevation. Once patients were enrolled, postoperative blood 
samples were collected. Specimens were analysed using the Troponin 
T hs (highly sensitive) immunoassay (Roche Diagnostics, Germany).
After approval from the Human Research Ethics Committee of 
the University of Cape Town (ref. no. 818/2014), data collection 
was commenced. Theatre lists were interrogated and patients with 
appropriate inclusion criteria were identified. Informed consent was 
obtained postoperatively, after which appropriate blood samples 
were taken. In the majority of patients (90.6%), one blood sample 
was taken within 24 hours of surgery. In the remainder, a second 
sample was taken within 72 hours. If two samples were taken, the 
highest troponin elevation was recorded. MINS was diagnosed if the 
postoperative hs-cTnT level was >33 ng/L.
As sampling only commenced after surgery, we could not identify 
patients with pre-existing cTnT elevation. Known preoperative 
myocardial infarction, pulmonary embolism, sepsis and renal 
dysfunction were therefore also grounds for exclusion because of 
the direct or indirect influence of these conditions on measured 
postoperative cTnT. Renal impairment was defined using international 
guidelines.[11,12] Further exclusion criteria included pre-existing 
hypotension and low-risk surgery such as ophthalmic and superficial 
plastic surgery. Other comorbidities were identified during the patient 
interview. Postoperative mortality data were not collected.
A post hoc decision was made to present some of the key 
characteristics of the Groote Schuur Hospital cohort, the SA vascular 
surgery cohort and the VISION cohort in order to provide further 
insight into the incidence of MINS in the Groote Schuur patients.[3,8] 
A statistical comparison of these characteristics between the Groote 
Schuur cohort and the VISION cohort was conducted.
Statistical analysis
Based on previous studies, a prevalence of MINS of 10 - 15% was 
estimated for our study population. On this basis, a sample size of 
219 - 266 would be required for a 95% CI of 10% for the estimate of 
the prevalence of MINS. A sample size of 300 was targeted.
Statistical analysis was done using Minitab 17 Statistical Software 
(Minitab, USA).[13] Continuous variables were described using sample 
means and standard deviations (SDs) and categorical variables 
using sample medians and interquartile ranges. Where statistical 
comparisons were made between continuous variables, the unpaired 
t-test was used, while categorical data were compared using the χ2 test 
or the χ2 test with Yates’s correction, as appropriate.
Results
During the data collection period (16 months), theatre lists were 
actively interrogated for only 39 weeks owing to researcher availability. 
For this reason, convenience sampling was our method of selection. 
During that time, ~1 100 patients underwent elective surgery, of 
whom 301 were eligible. The flow diagram of patient recruitment 
is shown in Fig. 1. The majority of initial exclusions were because 
of inappropriate age and/or low-risk surgery. The final number of 
patients included was 244.
The patient demographic details, surgical categories and co -
morbidities are shown in Table 1. The majority of patients were in 
the younger age category, 45 - 65 years. General and gynaecological 
Table 1. Patient characteristics
Included patients, N 244
Females, n (%) 139 (57.0)
Age (years)
Mean (SD) 60.5 (9.4)
45 - 64, % (95% CI) 68.9 (62.8 - 74.3)
65 - 75, % (95% CI) 23.8 (18.8 - 29.5)
>75, % (95% CI) 6.6 (4.0 - 10.5)
Surgical categories, n (%)
General 63 (25.8)
Gynaecological 52 (21.3)
Orthopaedic 40 (16.4)
Urological 27 (11.1)
Vascular 18 (7.4)
Otolaryngological 16 (6.6)
Thoracic 9 (3.7)
Neurological 3 (1.2)
Comorbidities*
Median (IQR) 1 (1 - 2)
Hypertension, n (%) 161 (66.0)
Malignancy, n (%) 78 (32.0)
Smoking, n (%) 69 (28.3)
Diabetes mellitus, n (%) 50 (20.5)
Hypercholesterolaemia, n (%) 47 (19.3)
Previous myocardial infarction, n (%) 20 (8.2)
Previous stroke, n (%) 15 (6.1)
Previous heart failure, n (%) 6 (2.5)
*Since some patients suffered from more than one comorbidity, these percentages do not 
add up to 100.
SD = standard deviation; CI = confidence interval; IQR = interquartile range.
Theatre list interrogation – convenience sampling
Surgery
Patients tting inclusion criteria
n=301
Consent
Declined, n=1           n=300
Specimen collection
Sampling errors, n=12         n=288
Other exclusions 
Renal impairment, n=35        n=253
High-sensitivity cardiac troponin T results
Lost, n=9                                                        Included, n=244
Fig. 1. Flow diagram of patient recruitment.
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surgery were the most common operations performed, which explains 
the higher proportion of female participants. Hypertension and 
malignancy were the most frequently recorded comorbidities. The 
hs-cTnT results are reported in Table 2.
The incidence of MINS was 4.9% (95% CI 2.8 - 8.5). There were 
inadequate data for multivariate regression analysis to investigate 
associations between patient or surgical risk factors and MINS.
Comparisons between the Groote Schuur, SA vascular and VISION 
cohorts are shown in Table 3. There was no significant difference in the 
incidence of MINS between the Groote Schuur and VISION studies. 
The Groote Schuur cohort had younger patients, fewer male patients 
and more hypertension. The Groote Schuur patients underwent more 
elective and vascular surgery than the VISION cohort.
Discussion
The main finding of this study was that the incidence of MINS in the 
elective elevated-risk surgical population in SA was comparable to 
reports from a large international study. It was impossible to perform 
a risk-adjusted analysis to compare the incidence of MINS between 
the Groote Schuur and VISION cohorts. A previous comparison 
between the South African Surgical Outcomes Study (SASOS) and 
the European Surgical Outcomes Study (EuSOS) suggested that 
SA surgical patients have a lower risk profile than surgical patients 
in Europe.[14] The patients in our study probably had a lower 
cardiovascular risk profile, as they were younger, included fewer 
males and had more elective surgery than the VISION cohort, as 
seen in Table 3. This has important public health implications for SA, 
because of the major morbidity and mortality associated with MINS.
Current perioperative morbidity rates translate into major 
complications in ~7 million patients and 1 million deaths per 
annum in the immediate perioperative period, since >200 million 
surgical operations are performed worldwide per year.[1] Studies 
from high-income countries suggest that 50% of major adverse 
perioperative events could be avoided.[1] Research on the cause and 
prevention of perioperative complications could therefore benefit 
global healthcare.
Myocardial ischaemia remains a major cause of perioperative 
morbidity and mortality.[15] To provide some perspective, 7% of 
medical patients who are treated in hospital for an acute myocardial 
infarction die within 30 days.[16] Patients may present with myocardial 
ischaemia either as a medical emergency or in the perioperative 
period. Both appear to have a significant 30-day mortality, but their 
clinical presentations are very different. The diagnosis of myocardial 
infarction in medical patients relies on clinical symptoms and signs 
in addition to positive special investigations (electrocardiogram, 
cardiac biomarkers, cardiac imaging studies).[17] A recent review 
suggests that the high proportion of silent presentations and the 
lack of high-grade evidence for therapeutic interventions could 
explain the hesitancy of perioperative clinicians to adopt MINS as 
a significant perioperative event.[18] However, it is clear that MINS 
results in significant morbidity and mortality and poses a significant 
public health burden.[5]
Cardiac biomarkers utilised for the diagnosis of myocardial 
infarction require predefined reference limits. These limits or cut-
off values are derived from healthy individuals.[19-21] Analysis of data 
from the VISION study showed not only that elevation of the cardiac 
biomarker cTnT was the strongest predictor of 30-day mortality, 
but also that the magnitude of troponin elevation correlated with 
risk. The VISION study attempted to predict mortality related to 
increasing levels of fourth-generation cTnT, in combination with the 
clinical presentation. Adding positive symptomatology to the model 
did not change the diagnostic threshold, and the diagnosis had the 
same prognostic importance for mortality as a myocardial infarction 
diagnosed using the Universal Definition of Myocardial Infarction.[5]
Correlations between the fourth- and fifth-generation cTnT test 
do exist. A fourth-generation cTnT level of 30 ng/L correlates with 
a fifth-generation cTnT (hs-cTnT) level of ~53 ng/L. However, a 
substudy of the VISION investigation found that the 95th percentile 
value for perioperative patients was 33 ng/L (95% CI 26 - 49 ng/L) 
for hs-cTnT.[6,22] The cumulative proportion of patients with a fourth-
generation cTnT level >30 ng/L was 9%, compared with 7 - 10% 
>33 ng/L using the hs-cTnT.
Table 2. High-sensitivity cTnT results at Groote Schuur 
Hospital
cTnT undetectable, n (%) 42 (17.2)
cTnT (ng/L), median (IQR) 7 (4 - 14) 
cTnT (ng/L), median >33 ng/L (IQR) 60 (37 - 83)
cTnT >99th percentile*, n (%) (95% CI) 55 (22.5) (17.8 - 28.2)
cTnT >33 ng/L†, n (%) (95% CI) 12 (4.9) (2.8 - 8.5)
cTnT >53 ng/L, n (%) (95% CI) 7 (2.9) (1.3 - 5.9)
cTnT = cardiac troponin T; IQR = interquartile range; CI = confidence interval.
*>14 ng/L.
†Primary outcome definition.
Table 3. Comparison between the GSH cohort, the SA vascular surgical cohort and the VISION study[3,8]
GSH (N=244)
SA vascular cohort 
(N=788) VISION (N=15 133) p-value*
Age (years), mean (SD) 60.5 (9.4) 58.3 (14.2) NR
Age 45 - 64 years, n (%) 168 (68.9) NR 7 436 (50.9) <0.001
Males, n (%) 105 (43.0) 512 (65.0) 7 339 (49.5) 0.044
Hypertension, n (%) 161 (66.0) 540 (68.5) 7 709 (50.9) <0.001
Diabetes mellitus, n (%) 50 (20.5) 338 (42.9) 2 952 (19.5) 0.761
History of coronary artery disease, n (%) 20 (8.2) 275 (34.9) 1 832 (12.1) 0.078
History of stroke, n (%) 15 (6.1) 159 (20.2) 696 (4.6) 0.323
History of heart failure, n (%) 6 (2.5) 37 (4.7) 703 (4.6) 0.151
Vascular surgery, n (%) 18 (7.4) 788 (100) 504 (3.3) 0.001
Elective surgery, n (%) 244 (100) NR 12 991 (85.8) <0.001
Incidence of MINS, n/N (%) 12/244 (4.9) 25/509 (5.0)† 1 200/15 065 (8.0) 0.080
GSH = Groote Schuur Hospital; SA = South African; VISION = Vascular Events In Non-cardiac Surgery Patients Cohort Evaluation; SD = standard deviation; NR = not recorded;  
MINS = myocardial injury after noncardiac surgery.
*Comparison between GSH and VISION cohorts.
†Reported troponin level above the 99th centile reference range.
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The fifth-generation cTnT (hs-cTnT) used in the present study has 
improved diagnostic sensitivity to nearly 100% in patients presenting 
as a medical emergency; a level >14 ng/L suggests myocardial 
necrosis.[21,23] The increased sensitivity has added complexity to 
the interpretation of perioperative changes in troponin levels, 
and specificity is reduced because of the many alternative causes 
of troponin elevation during this period.[21] Carbon monoxide 
poisoning, renal failure, heart failure, acute pericarditis, acute 
exacerbation of chronic obstructive airway disease, chemotherapy-
related myocardial damage, pulmonary hypertension, pulmonary 
embolism, sepsis, stroke and subarachnoid haemorrhage can all 
result in cTnT elevations.[24-35] Not all of these elevations appear to 
affect prognosis consistently, especially in non-surgical patients. 
However, in the perioperative period cTnT elevation appears to 
be a robust marker for predicting outcome, and is independently 
associated with a 10% 30-day mortality.[5,36] Preoperative hs-cTnT 
elevation, as well as an absolute rise of >9 ng/L hs-cTnT, have 
consistently been shown to have a significant short- and long-term 
effect on perioperative mortality.[37]
Our study has implications for cardiovascular risk stratification 
in SA. Our patients have a similar incidence of MINS to that 
of international cohorts, despite a possible lower risk profile, 
which suggests that the current international cardiovascular risk 
prediction models may be inappropriate for SA patients and/or they 
may be incorrectly calibrated, resulting in an underestimation of 
cardiovascular risk in SA surgical patients. This finding is supported 
by recent literature which suggests that utilising the revised cardiac 
risk index in SA patients may be inappropriate, especially in vascular 
surgery.[9] Another confounder may be the HIV epidemic in southern 
Africa, with HIV-positive patients undergoing vascular surgery 
having fewer of the usually cited cardiovascular risk factors than 
HIV-negative patients, but similar perioperative morbidity and 
mortality.[7] The development of an appropriate and well-calibrated 
perioperative cardiovascular risk prediction model is necessary in 
SA. A large SA cohort is first necessary to determine calibration of 
cardiovascular risk factors in SA patients.
The evidence for preventive and therapeutic strategies for MINS 
is lacking.[18,38] The current literature suggests implementation of 
simple strategies when MINS is suspected, including appropriate 
surveillance in the form of regular screening of troponin levels.[18,38] 
Furthermore, intraoperative prevention should focus on optimising 
myocardial oxygen supply and demand. Once MINS is diagnosed 
in the postoperative setting, interdisciplinary management should 
be initiated. In addition, aspirin and statin therapy show potential 
benefit, and studies investigating specific therapeutic and preventive 
measures are in progress.[18]
Study limitations
Although we screened >1 100 patients, our sample size remained 
relatively small, and the event rate was lower than expected, so the 
primary outcome had a wider than anticipated CI. The incidence 
of MINS in our population was lower than we expected. This may 
be explained in part by our methodology of single postoperative 
troponin sampling per patient, while the VISION study had a 
median of three troponin samples per patient. Furthermore, VISION 
included both elective and emergency surgery, and as our study 
only included elective surgeries, this too may have led to a lower 
incidence of MINS. Together with the lower event rate, our study 
now appears to be underpowered to achieve all our secondary 
objectives of establishing associations with MINS. However, as our 
data suggest a similar incidence of MINS to an international cohort, 
we would recommend routine perioperative troponin surveillance for 
intermediate- to high-risk surgical patients in SA.
In addition, the intended multivariate analysis examining the 
association of patient factors and MINS could not be performed. The 
high exclusion rate was to avoid confounders for postoperative hs-cTnT 
elevation that may not have been secondary to myocardial ischaemia. 
It is possible that the incidence may be higher than reported, since we 
excluded many patients at high risk of cardiovascular complications 
who had comorbidities that may be associated with cTnT release due 
to causes other than ischaemia.
Conclusions
Since SA still lacks population-specific prognostic values for hs-cTnT, 
the present study serves as an initial indicator of the incidence of 
MINS, while also providing guidance for sample size calculation 
for future larger studies that could identify patient or surgical 
risk factors for poor outcomes due to MINS. This study failed to 
demonstrate a difference in the incidence of MINS between our 
SA cohort and the VISION cohort, although the study limitations 
weaken our conclusions. Although this study did not specifically 
examine the association between MINS and major perioperative 
morbidity and mortality in SA patients, the methodology of the 
VISION analysis suggests that the associated perioperative morbidity 
is universally applicable, and our study therefore suggests that 
MINS has significant implications for public health outcomes in SA. 
International guidelines promote the utility of troponin surveillance, 
and a recent study found troponin surveillance to be financially viable 
in SA.[39,40] Our data suggest that postoperative troponin surveillance 
is necessary in elevated-risk non-cardiac surgical patients in SA.
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